|
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems |
PAR-20-155 (R01 Clinical Trial Optional) |
09/08/2022 |
|
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research |
RFA-CA-21-006 (R33 Clinical Trial Not Allowed) |
09/30/2021 |
|
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research |
RFA-CA-21-004 (R33 Clinical Trial Not Allowed) |
09/29/2021 |
|
Advanced Development of Informatics Technologies for Cancer Research and Management |
RFA-CA-21-015 (U24 Clinical Trial Optional) |
11/18/2021 |
|
Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-20-314 (UH3 Clinical Trials Not Allowed) |
10/11/2023 |
|
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) |
PAR-20-313 |
10/11/2023 |
|
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention |
PAR-19-251 (R01 Clinical Trial Optional) |
11/09/2021 |
|
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention |
PAR-19-252 (R21 Clinical Trial Optional) |
11/09/2021 |
|
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research |
PAR-19-113 (R01 Clinical Trial Optional) |
01/08/2022 |
|
Co-infection and Cancer |
PAR-20-062 (R01 Clinical Trial Not Allowed) |
01/08/2023 |
|
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management |
RFA-CA-21-013 (R21 Clinical Trial Optional) |
11/18/2021 |
|
Early-Stage Development of Informatics Technologies for Cancer Research and Management |
RFA-CA-21-014 (U01 Clinical Trial Optional) |
11/18/2021 |
|
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer |
PAR-19-264 (R01 Clinical Trial Optional) |
12/11/2021 |
|
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research |
RFA-CA-21-005 (R21 Clinical Trial Not Allowed) |
09/30/2021 |
|
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research |
RFA-CA-21-003 (R21 Clinical Trial Not Allowed) |
09/30/2021 |
|
Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01- Clinical Trial Not Allowed) |
PAR-20-088 |
04/02/2022 |
|
Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21- Clinical Trial Not Allowed) |
PAR-20-081 |
04/02/2022 |
|
Notice of Correction to Application Types Allowed for PAR-20-053, Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection |
NOT-CA-20-067 (R01 Clinical Trial Not Allowed) |
01/08/2023 |
|
Notice of Special Interest (NOSI): Advancing Head and Neck Cancer Early Detection Research (AHEAD) |
NOT-CA-20-031 |
01/08/2022 |
|
Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers |
NOT-CA-21-028 |
01/08/2024 |
|
Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions |
NOT-CA-20-044 |
05/08/2023 |
|
Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit |
PAR-21-335 (U24 Clinical Trial Not Allowed) |
06/12/2024 |
|
Pancreatic Cancer Detection Consortium: Research Units |
PAR-21-334 (U01 Clinical Trial Optional) |
06/12/2024 |
|
Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection |
PAR-20-053 (R01 Clinical Trial Not Allowed) |
01/08/2023 |
|
Revision Applications to Support the Application of Informatics Technology for Cancer Research |
RFA-CA-21-018 (U01 Clinical Trials Optional) |
11/18/2021 |
|
Revision Applications to Support the Application of Informatics Technology for Cancer Research |
RFA-CA-21-019 (U24 Clinical Trial Optional) |
11/19/2021 |
|
Revision Applications to Support the Application of Informatics Technology for Cancer Research |
RFA-CA-21-017 (R01 Clinical Trials Optional) |
11/18/2021 |
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes |
PAR-20-277 (R21 Clinical Trials Not Allowed) |
09/08/2022 |
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes |
PAR-20-276 (R01 Clinical Trial Not Allowed) |
09/08/2022 |
|
Sustained Support for Informatics Technologies for Cancer Research and Management |
RFA-CA-21-016 (U24 Clinical Trial Optional) |
11/18/2021 |
|
Translational and Basic Science Research in Early Lesions (TBEL) |
RFA-CA-21-054 (U54 Clinical Trial Not Allowed) |
11/03/2021 |
|
Translational and Basic Science Research in Early Lesions (TBEL) Coordinating and Data Management Center |
RFA-CA-21-055 (U24 Clinical Trial Not Allowed) |
11/03/2021 |
